Skip to main content
Premium Trial:

Request an Annual Quote

Isis, Genzyme Submit Antisense Cholesterol Drug for European Approval

Premium

Isis Pharmaceuticals and Genzyme said this week that they have submitted their antisense-based cholesterol drug mipomersen for European market approval.

Specifically, the companies are seeking clearance to commercialize the 200 mg weekly dose of the drug for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

If approved, the companies said the drug would be marketed as Kynamro. A US regulatory submission is expected to be filed later this year.

Isis originally developed mipomersen, and Genzyme acquired the drug's rights in early 2008.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.